$1,951.65+$11.48 (+0.59%) on the dayAs of the close; data may be delayed.
MKL price, last 12 months
$2,192$1,712$1,952
Daily closes over the last 260 trading sessions: −4.2%. Highest close $2,191.90 on , lowest $1,712.45 on . Market data may be delayed.
Key stats
Previous close
$1,940.17
Open
$1,959.17
Day range
$1,931.01 – $1,964.95
52-week range
$1,704.17 – $2,207.59
Volume
57K
Avg volume (20 days)
62.4K
Market cap
$24.2B
Performance
1W−2.1%
1M+1.6%
3M+6.6%
6M+4.2%
YTD−9.9%
1Y−5.1%
vs S&P 500, 1Y−10.2 pts
Technicals and fundamentals
About Markel Group Inc.
Markel's primary business is property-casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.
Chart MKL with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full MKL chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.
Technicals
RSI (14)55.7mid-range
vs 50-day average+5.2%
vs 200-day average+2.5%price above both averages
MACDBelow signal
Daily range (ATR)1.8%average true range, % of price
52w low $1,704.1752w high $2,207.59
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)13.30.96x Finance, Insurance & Real Estate median (13.9)
P/E (forward)16.2
PEG1.87
Price / sales1.51
Price / book1.29
EV / EBITDA—
P/E since Jun 19.4 – 42.0
Company figures as of Nov 19, 2026.
Analysts
ConsensusHold3.1 on 1 (strong buy) to 5 (strong sell)
Analysts6
Average target$1,980.17+2.3% from today
Price targets are opinions and tend to lean optimistic.
Seasonality
+2.6
J
+0.4
F
+1.1
M
-3.1
A
+3.8
M
+1.2
J
+1.2
J
-3.0
A
-3.8
S
+5.3
O
+3.9
N
+0.3
D
Average return in each calendar month, Oct 31, 2021 to Oct 31, 2026. 6 years is 6 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
−5
+2
−8
−7
+2
+8
−4
−4
−5
+9
−13%
2025
+6
+6
−3
−3
+7
+3
+1
−2
−2
+3
+5
+3
+25%
2024
+5
−0
+2
−4
+13
−4
+4
−2
−2
−2
+16
−3
+22%
2023
+7
−6
−4
+7
−4
+5
+5
+2
−0
−0
−2
−1
+8%
2022
−0
+1
+19
−8
+1
−6
+0
−8
−9
+11
+10
−1
+7%
2021
+10
−9
+3
+3%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
Strong Q3 results with 29% industrial division growth, successful $1.2B adverse development protection securing legacy risk certainty, aggressive $315M share buyback program reducing share count by 10% over 5 years, and management confidence in portfolio positioning and capital allocation strategy. These factors demonstrate disciplined execution and shareholder value creation.
The article highlights poor recent underwriting results, vulnerability to market swings, lack of dividend payments, and the author's decision not to invest despite fair valuation. The company is underperforming relative to its historical track record.
MKL's new CORE product launch presents growth opportunity but faces execution risks. Stock is undervalued (P/B 1.15X vs industry 2.69X) but has underperformed (-7.8% YoY), and EPS estimates have declined in the past 60 days. The company carries a Zacks Rank #4 (Sell) rating, indicating cautious outlook despite strategic expansion.
Cited as a successful example of an insurer that has beaten the market over a multidecade timeframe using a Berkshire-style approach, demonstrating that the strategy can work.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.